– USA, MA – Atea Pharmaceuticals, Inc. (Nasdaq: AVIR), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, today announced the appointment of Barbara Duncan to its Board of Directors as Chair of the Audit Committee.
“We are delighted to welcome Barbara to the Atea Board of Directors. Her financial acumen combined with her considerable experience advising a variety of biopharmaceutical companies will make Barbara’s guidance invaluable to Atea as we navigate the public markets and advance our antiviral pipeline,” said CEO and Founder, Dr. Jean-Pierre Sommadossi.
About Barbara Duncan
Ms. Duncan previously served as CFO and Treasurer at Intercept Pharmaceuticals. Before her leadership role with Intercept, Ms. Duncan was CFO and then CEO at DOV Pharmaceutical, which was sold to Euthymics Bioscience. Before that, she served as VP, Corporate Finance – Global Healthcare at Lehman Brothers and as Director of Corporate Finance at SBC Warburg Dillon Read.
Ms. Duncan currently serves on the Board of Directors of Adaptimmune Therapeutics, Fusion Pharmaceuticals, Jounce Therapeutics, ObsEva SA, and OVID Therapeutics.
“I am proud to join Atea at this critical juncture as the Company recently transitioned to a publicly traded entity,” said Barbara Duncan. “Importantly, I am excited to be a part of the team working to make a difference in this global pandemic through the advancement of AT-527, an oral product candidate for the treatment of patients suffering from COVID-19.”
Ms. Duncan received an M.B.A. from the Wharton School, University of Pennsylvania, and a B.S. from Louisiana State University.
About Atea Pharmaceuticals
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company’s deep understanding of antiviral drug development, nucleoside biology, and medicinal chemistry, Atea has built a proprietary purine nucleotide prodrug platform to develop novel product candidates to treat single-stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2, the virus that causes COVID-19, hepatitis C virus infection, dengue virus, and respiratory syncytial virus.
For more information: https://ateapharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
